Objective: The introduction of lower profile endografts expanded the application of aortic endovascular repair. However, evidence about their durability is still scarce. The objective of this study was to assess longer term durability of the Zenith Alpha Thoracic Stent Graft (Cook Inc, Bloomington, Ind) after thoracic endovascular aortic repair.
Today, thoracic endovascular aortic repair (TEVAR) is a well-established treatment option for pathologic processes of the thoracic aorta. The minimally invasive character of the procedure, without the necessity of extensive surgical exposure and aortic clamping, provides an advantage over the open surgical repair in terms of comparable survival and lower perioperative complications. 1, 2 However, demanding access vessel anatomy represents a major limitation, leading to increased morbidity and mortality or exclusion of patients from endovascular therapy. In this context, the low-profile Zenith Alpha Thoracic Endovascular Stent Graft (Cook Inc, Bloomington, Ind) was designed to overcome such anatomic obstacles and to increase the applicability of TEVAR without compromising the outcomes of the procedure. The smaller profile and the flexibility of the delivery system represent a remarkable advantage of the new endograft compared with the previous Zenith TX-2 Thoracic Stent Graft. 3 Among the stent graft components, the graft fabric is a major determinant of the endoprosthesis profile. Thus, the Zenith Alpha stent graft features a thinner woven polyester fabric. In addition, the stent material is optimized to contribute to a lower profile. 4 A number of reports have addressed shortterm results; however, one major concern is the effectiveness of this stent graft in the long run. [5] [6] [7] Therefore, this study sought to evaluate the Zenith Alpha Thoracic Stent Graft under the aspect of durability.
METHODS
Study cohort. Demographics, comorbidities, and imaging data of all consecutive patients undergoing implantation of the Zenith Alpha Thoracic Stent Graft for aortic repair were prospectively collected. In this study, all patients treated for aortic aneurysms as well as penetrating aortic ulcers and with a minimum follow-up of 1 year were eligible for an intention-to-treat analysis. Informed consent was obtained before the procedure. This study is in accordance with the principles of the Declaration of Helsinki, and the study protocol was approved by the local Ethic Committee (No. 2009-034-b-m).
End points and definitions. The primary outcome measure was the ongoing clinical success of the procedure. In accordance with the reporting standards for TEVAR, ongoing clinical success is defined as clinical success including freedom from secondary surgical or Secondary outcome parameters assessing TEVAR durability were freedom from graft migration of >5 mm, fracture, and type III endoleaks.
Moreover, incidence of type II endoleak, freedom from all-cause mortality, and freedom from access vessel complications were assessed. Finally, procedure-related morbidity comprising myocardial infarction, cerebrovascular accidents, and spinal cord ischemia, all related to the index procedure, was assessed.
Imaging analysis and surveillance protocol. Aquarius iNtuition (TeraRecon, Foster City, Calif) was used for imaging analysis. The preoperative maximum outerouter thoracic diameter was recorded. Proximal neck length and diameter were measured using the vessel centerline of flow technique. Aortic arch angulation was assessed by measuring the maximum radius of the lesser aortic arch curvature. The thoracic aorta tortuosity index was evaluated as the ratio between the straightened line and the length on the centerline from the proximal edge of the offspring of the innominate artery to the proximal edge of the origin of the celiac trunk.
Iliac calcification was regarded as being present if >50% of the vessel wall circumference was calcified. Iliac artery length and minimum inner diameter were recorded. Iliac tortuosity was measured, dividing the length of the common and external iliac artery by the shortest possible line between the ends of these arteries. Postoperative imaging analysis included postoperative maximum aneurysm diameter, patency and integrity of the graft, migration ($5 mm) of the stent graft, and any type of endoleak. Proximal bird-beak configuration was regarded as present in case of a gap of >5 mm between the first covered stent of the stent graft and the aortic proximal wall. The degree of oversizing was defined as the percentage difference between the maximum proximal and distal stent graft diameter and the maximum diameter of the respective aortic portion in which it was implanted. The postoperative surveillance protocol consisted of computed tomography angiography (CTA) of the aorta (1-mm thickness) and radiography.
All patients with glomerular filtration rate >60 mL/min/ 1.73 m 2 or on dialysis underwent CTA before discharge, after 1 year, and then annually up to 5 years. Patients with chronic or acute renal disease (15 < glomerular filtration rate < 60 mL/min/1.73 m 2 ) underwent non-contrast-enhanced computed tomography in the same intervals. All preoperative measurements were performed by the operating vascular surgeon and re-evaluated by an independent radiologist; the postoperative imaging studies were re-analyzed by an independent radiologist with advanced experience in endovascular aortic surgery and two experienced vascular surgeons.
Device description. We have described the device in detail elsewhere. 4 Briefly, the Zenith Alpha Thoracic Stent Graft features a tightly woven polyester graft, sewn to self-expanding nitinol stents with monofilament polypropylene sutures. This allows loading of the graft in low-profile delivery systems, ranging in sizes between 16F and 20F.
Procedure details. The indication for and planning of all TEVARs were based on thoracoabdominal thinsliced CTA. A three-dimensional workstation software (Aquarius iNtuition 4.4.7) was used for procedure planning. Beforehand, the necessity of adjunctive procedures (eg, subclavian-carotid transposition/bypass, chimney graft for the left subclavian artery, iliofemoral conduits, or the paving and cracking technique) was evaluated. The indication for and the particular choice of the graft were at the surgeon's discretion. Among the main reasons for selecting the Zenith Alpha Thoracic Stent Graft were demanding access vessel and aortic arch morphologic features.
During the procedure, intravenous heparin was administered to reach an activated clotting time corridor of 250 to 300 seconds. Where possible, we obtained completely percutaneous femoral access by means of the preclose technique (Prostar XL; Abbott Vascular, Santa Clara, Calif) as described elsewhere. 9 Additional access was gained through the left brachial artery, when necessary. In some cases, the orifices of target vessels were marked with an angiographic catheter. In patients with involvement of aortic branches, two-dimensional/threedimensional fusion imaging was employed to facilitate the deployment. 10 After the necessary graft length was validated with a graded pigtail catheter, the proximal component was deployed. In most cases, a permissive hypotension of <80 mm Hg systolic blood pressure sufficed; when necessary, rapid pacing of the heart was induced. When indicated, a distal component was deployed, aiming for an overlap of at least three stents. A Reliant balloon (Medtronic, Santa Rosa, Calif) was then used for stent graft modeling. After deployment of the graft, completion angiography was performed to ensure adequate placement of the graft and to rule out endoleaks. 
RESULTS
Patient sample selection and baseline data. From August 2010 to December 2016, 276 patients were treated for aneurysmal disease or penetrating aortic ulcer of the thoracic and thoracoabdominal aorta at our institution. Of these, 219 were treated by endovascular means of TEVAR; 149 patients underwent an elective or urgent treatment with the Zenith Alpha Thoracic Stent Graft. The 70 consecutive patients treated between August 2010 and October 2015 had a minimum followup of 1 year and were included in the study cohort. Table I summarizes the demographic and clinical characteristics of the study population; procedural details are provided in Table II .
Ongoing clinical success. The ongoing clinical success amounted to 87.1% (61 patients) after a mean imaging follow-up of 22.3 6 15.9 months. Of the nine patients, six were treated outside the instructions for use, with a proximal landing zone #20 mm (n ¼ 4) or a narrow radius of the inner aortic curvature (n ¼ 3). Details are provided in Table III .
Mortality. Thirty-day mortality was 7.1% (n ¼ 5). The first case was a 92-year-old woman with a highly symptomatic thoracic aortic aneurysm with a maximum aneurysm diameter of 120 mm causing dysphagia and dyspnea. The patient ultimately died of exacerbation of New York Heart Association stage IV congestive heart failure. In the second case, the patient died of septic shock secondary to mesenteric ischemia in the setting of atrial fibrillation. In one case, the cause of death was unknown. The other two deaths were caused by myocardial infarction and pneumonia, respectively. During a maximal follow-up of 76 months, the overall mortality rate amounted to 17.1%, with all the postdischarge deaths not related to the endovascular intervention (Figs 1 and 2 ).
Endoleaks. There were three type IA endoleaks detected on the postoperative computed tomography scan. The first patient had been treated with a parallel graft technique and developed a gutter after placement of the chimney graft in the left subclavian artery. The endoleak disappeared spontaneously after 6 months. A combined type IA and type II endoleak was detected in the 92-year-old woman mentioned before and was treated successfully by aneurysmal sac and left subclavian artery coil embolization 10 days after the index procedure. The third patient had a type IA endoleak after treatment of a thoracic aneurysm and was scheduled for reintervention. He experienced abdominal pain and died before laparotomy could be performed. Type IB endoleaks occurred in two patients (3%), although there was no aneurysm sac expansion, and thus a reintervention was not considered necessary at that time. There were five cases of type II endoleak (7%). The CTA follow-up did not show any type III or type IV endoleaks.
Midterm durability. The mean postoperative aneurysm diameter was 61.2 6 18.25 mm. There was no case of stent fracture; stent graft migration was observed in one case (1.4%; Fig 3) . Aneurysm sac enlargement was detected in one case. A 76-year-old patient had a type II endoleak from bronchial arteries, leading to an aneurysmal sac enlargement of 17 mm after 23 months. Because the patient was asymptomatic, he was treated conservatively.
Access vessel management. In four cases (5.7%), balloon dilation of the iliac arteries was required before stent graft deployment, and three (4.3%) patients received an iliofemoral conduit. In 87.1% of the cases, the treatment was conducted through a totally percutaneous transfemoral access (61 patients). There were access vessel complications in three cases (4.3%). One patient had a false aneurysm after percutaneous access vessel closure, one patient had an access vessel dissection, and one patient had both.
Other secondary end points. The incidence of spinal cord ischemia was 1.4% (n ¼ 1), and it was related to treatment of a long thoracoabdominal aortic segment. There was no cerebrovascular complication related to the index procedure. The mean duration of in-hospital stay was 11.16 6 5.13 days. Anatomic characteristics are summarized in Table IV .
DISCUSSION
The Cook Zenith Alpha Thoracic Stent Graft is one of the first low-profile devices for treatment of thoracic aortic diseases. In the past, this device has been evaluated thoroughly in the setting of elective thoracic aortic aneurysm repair and traumatic injury. 5, 12 These and other studies revealed safety and efficacy, with technical success ranging from 90% to 100%. Specific advantages of this stent graft are its lower profile and enhanced flexibility. 4 This translates to extended applicability, especially in patients with difficult access vessels. 3 However, as all the aforementioned studies examined the short-term performance of this device, it remains unclear whether the favorable results of the Zenith Alpha Thoracic Stent Graft remain durable. We consider that this is especially important because the graft material alterations employed to achieve lower profile could lead to limited durability, such as stent fractures, stent graft migration, and type III endoleak, resulting in aneurysm growth. Hence, the focus of this study was to evaluate results of this device in a midterm time frame based on CTA imaging. Beginning with the stent material, which now consists of nitinol, there was no stent fracture observed. Other low-profile devices used in the abdominal segment show similar results in even longer time frames. 13, 14 This finding harmonizes well with the overall experience with nitinol-based stent grafts, which are used in the majority of the currently available devices. 15, 16 Second, stent graft migration, secondary to insufficient oversizing, aortic neck degeneration, or material failure, is a potential cause of type I endoleak. 17 In our cohort of patients, we found one case of migration. With an incidence of 1.4%, this correlates well with stent graft migration rates reported in the literature. 15, 16 Last, the thinner graft material is a potential cause of type III and type IV endoleak and subsequent aneurysm sac expansion. Whereas we detected no type III endoleak, there was one case of aneurysm expansion. In this case, the patient had a type II endoleak from bronchial arteries on postoperative CTA. Aneurysm growth rates after TEVAR vary between 1% and 3.4% in the literature, corresponding well with our findings.
5,16
Our results show that once initial technical success is achieved, TEVAR with this stent graft continues to be safe and efficacious. An ongoing clinical success of 87.1% is acceptable, considering the large proportion of patients having unfavorable anatomic morphologic features. This is reflected by the fact that almost 50% of the patients had anatomic criteria outside the limits of instructions for use, with 27.1% of the patients having aneurysm neck lengths of #20 mm and 18% having aortic arch curvature radii of #2 cm. Moreover, >41% had severe iliac calcification with a mean iliac diameter of 6 mm; 20% of the patients were treated under urgent or emergent conditions.
Limitations. This study has several limitations. First, it is a retrospective review of prospectively collected data on device performance. However, it reflects real-life results of TEVAR under unfavorable conditions. Furthermore, the patient sample in this study is small, and we are reporting data from a single-center institution. Therefore, results must be confirmed by an ongoing multicenter, prospective study, which is expected to be published in the near future. Third, radiologic measurements were performed by two experienced vascular surgeons; however, these measurements have not been validated by means of inter-rater and intra-rater analyses. More longterm results based on sound data are needed.
CONCLUSIONS
The Zenith Alpha Thoracic Stent Graft appears to maintain its favorable results in a longer time frame. Although it is built on a low-profile platform, TEVAR with the Zenith Alpha Thoracic Stent Graft remained durable with a low incidence of aneurysm sac growth and migration. Multicenter prospective randomized trials are needed to validate these results.
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